Are you Dr. Kaye?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 31 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
500 Kendall St
Cambridge, MA 02142Phone+1 617-768-6129
Summary
- Dr. Edward Kaye, MD is a Child Neurologist in Cambridge, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Pennsylvania, and Texas. He is a Lecturer on Neurology at Boston Children's Hospital.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Neurology, 2015 - 2018
Boston University Medical CenterResidency, Neurology, 1978 - 1981
Loyola University Medical CenterResidency, Pediatrics, 1975 - 1978
Loyola University Chicago Stritch School of MedicineClass of 1975
Certifications & Licensure
MA State Medical License 1986 - 2026
PA State Medical License 1996 - 2018
TX State Medical License 1983 - 1987
IL State Medical License 1977 - 1984- American Board of Pediatrics Pediatrics
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Clinical Trials
- Study of Eteplirsen in DMD Patients Start of enrollment: 2014 Nov 17
Publications & Presentations
PubMed
- 183 citationsChildhood ataxia with diffuse central nervous system hypomyelinationRaphael Schiffmann, Johanna R. Möller, Bruce D. Trapp, Henry H L Shih, Robert G. Farrer
Annals of Neurology. 1994-03-01 - 397 citationsAntisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyMarco A. Passini, Jie Bu, Amy M. Richards, Cathrine Kinnecom, S. Pablo Sardi
Science Translational Medicine. 2011-03-02 - 496 citationsEteplirsen for the treatment of Duchenne muscular dystrophyJerry R. Mendell, Louise R. Rodino-Klapac, Zarife Sahenk, Kandice Roush, Loren Bird
Annals of Neurology. 2013-11-01
Press Mentions
- Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business UpdatesAugust 10th, 2021
- Stoke Therapeutics to Present at Upcoming Investor Conferences in AugustAugust 3rd, 2021
Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth ConferenceFebruary 24th, 2020- Join now to see all
Grant Support
- Molecular Genetic Studies Of GM1 GanglionNational Institute Of Neurological Disorders And Stroke1994
- Molecular Genetic Studies Of Human GM1 GanglionNational Institute Of Neurological Disorders And Stroke1990–1993
